Toward the pharmacogenomics of cystic fibrosis - An update

Pharmacogenomics

Volumn 5, Issue 7, 2004, Pages 861-878

  Sangiuolo, Federica ^a   D'Apice, Maria Rosaria ^a   Gambardella, Stefano ^a   Di Daniele, Nicola ^a   Novelli, Giuseppe ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Allelic heterogeneity; CFTR mutations; CFTR pathies; Cystic fibrosis; Gene therapy; Genotype phenotype correlation; Modifier gene; Neonatal screening; Pharmacological approach

Indexed keywords

4 BROMOLEVAMISOLE; 4 PHENYLBUTYRIC ACID; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; AMILORIDE; APIGENIN; ASCORBIC ACID; BUPHENYL; BUTYRIC ACID; CALNEXIN; CALYCULIN A; CHLORIDE CHANNEL; CYCLOSPORIN; DELTAMETHRIN; DEUTERIUM OXIDE; DIMETHYL SULFOXIDE; FORSKOLIN; GENISTEIN; GENTAMICIN; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE; ISOBUTYLMETHYLXANTHINE; KAEMPFEROL; LEVAMISOLE; MANNOSE BINDING LECTIN; NEURONAL NITRIC OXIDE SYNTHASE; POLYOL; QUERCETIN; S NITROSOGLUTATHIONE; TRANSFORMING GROWTH FACTOR BETA1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSINOGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DRUG BINDING; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNOREACTIVITY; MOLECULAR MECHANICS; NEWBORN SCREENING; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PHENOTYPE; PROTEIN DEGRADATION; REVIEW; SIDE EFFECT; TRANSCRIPTION INITIATION;

CYSTIC FIBROSIS; HUMANS; PHARMACOGENETICS;

EID: 6344289404     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.7.861     Document Type: Review

References (173)

1. Sangiuolo F, D'Apice M, Bruscia E, Lucidi V, Novelli G: Towards the pharmacogenomics of cystic fibrosis. Pharmacogenomics 3(1), 75-87 (2002).
2. Dodge JA, Morison S, Lewis PA et al.: Incidence, population and survival of cystic fibrosis in the UK, 1968-95. Arch. Dis. Child. 77, 493-496 (1997).
3. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB: CFTR is a conductance regulator as well as a chloride channel. Physiol. Rev. 79(Suppl. 1), S145-S166 (1999)
4. Kerem B, Rommens KM, Buchanan D et al.: Identification of the cystic gene, genetic analysis. Science 245, 1073-1080 (1989).
5. Riordan JR, Rommens JM, Kerem BS et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073 (1989).
6. Rommens JM, Iannuzzi MC, Kerem BS et al.: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245, 1059-1065 (1989).
7. Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur. J. Hum. Genet. 4, 65-73 (1996).
8. Anderson MP, Gregory RJ, Thompson S et al.: Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253, 202-205 (1991).
9. Schwiebert EM, Egan ME, Hwang TH et al.: CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 81, 1063-1073 (1995).
10. - channel and CFTR-associated ATP channel: distinct pores regulated by common gates. EMBO J. 17, 898-908 (1998).
11. Egan M, Flotte T, Afione S et al.: Defective regulation of outwardly rectifying Cl channels by protein kinase A corrected by insertion of CFTR. Nature 358, 581-584 (1992).
12. Hryciw DH, Guggino WB: Cystic fibrosis transmembrane conductance regulator and the outwardly rectifying chloride channel: a relationship between two chloride channels expressed in epithelial cells. Clin. Exp. Pharmacol. Physiol. 27(11), 892-895 (2000).
13. Ismailov II, Awayda MS, Jovov B et al.: Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 271, 4725-4732 (1996).
14. Stutts MJ, Canessa CM, Olsen JC et al.: CFTR as a cAMP-dependent regulator of sodium channels. Science 269, 847-850 (1995).
15. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC: Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. 2, 21-25 (1992).
16. Bannykh SI, Bannykh GI, Fish KN, Moyer BD, Riordan JR, Balch WE: Traffic pattern of cystic fibrosis transmembrane regulator through the early exocytic pathway. Traffic 1(11), 852-870 (2000).
17. Ward CL, Kopito RR: Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild type and mutant proteins. J. Biol. Chem. 269, 25710-25718 (1994).
18. Kopelman H, Durie P, Gaskin K et al.: Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N. Engl. J. Med. 312, 329-334 (1985).
19. Dodge JA: Male fertility in cystic fibrosis. Lancet 346, 587-588 (1995).
20. Kopito LE, Kosasky HJ, Shwachman H: Water and electrolytes in cervical mucus from patients with cystic fibrosis. Fertil. Steril. 24, 512-516 (1973).
21. Cystic Fibrosis Foundation: Cystic Fibrosis Foundation Patient Registry Annual Report (2000).
22. Fogarthy A, Hubbard R, Britton J: International comparison of median age at death from cystic fibrosis. Chest 117, 1656-1660 (2000).
23. Mahadeva R, Webb K, Westerbeek RC et al.: Clinical outcome in relation to care in centers specialising in cystic fibrosis: cross-sectional study. Br. Med. J. 316, 1771-1775 (1998).
24. Schechter MS, Shelton BJ, Margolis PA et al.: The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am. J. Respir. Crit. Care. Med. 163, 1331-1337 (2001).
25. Cohn JA: The diagnosis of CF in patients with non-classical phenotypes. Pediatr. Pulmonol. 20, 89-90 (2000).
26. Tsui LC, Buchwald M, Barker D: Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 230(4729), 1054-1057 (1985).
27. Girodon-Boulandet E, Cazeneuve C, Goossens M: Screening practices for mutations in the CFTR gene ABCC7. Hum. Mutat. 15(2), 135-149 (2000).
28. Audrezet MP, Chen JM, Raguenes O et al.: Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms. Hum. Mutat. 4, 343-357 (2004).
29. Morral N, Bertranpetit J, Estivill X et al.: The origin of the major cystic fibrosis mutation (ΔF508) in European populations. Nat. Genet. 7, 169-175 (1994).
30. Bobadilla JL, Farrell MH, Farrell PM: Applying CFTR molecular genetics to facilitate the diagnosis of cystic fibrosis through screening. Adv. Pediatr. 49, 131-190 (2002).
31. Hamosh A, Rosenstein BJ, Cutting GR: CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum. Mol. Genet. 1(7), 542-544 (1992).
32. Cheng SH, Grego RJ, Marshall J et al.: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-834 (1990).
33. Strong TV, Smit LS, Turpin SV et al.: Cystic fibrosis gene mutations in two sisters with mild disease and normal sweat electrolyte levels. N. Eng. J. Med. 325, 1630-1634 (1991).
34. Welsh NJ, Smith AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73, 1251-1254 (1993).
35. Anderson MP, Walsh MJ: Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science 257, 1701-1704 (1992).
36. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ: Mutations in CFTR associated with mild disease form Cl channels with altered pore properties. Nature 362, 160-164 (1993).
37. Highsmith WE Jr, Burch LH, Zhou Z et al.: Identification of a splice site mutation (2789-5G-A). Hum. Mut. 9, 332-338 (1997).
38. Zielenski J, Markiewicz D, Lin SP, Huang FY, Yang-Feng TL, Tsui LC: Skipping of exon 12 as a consequence of a point mutation ( 1898-5G-T) in the cystic fibrosis transmembrane conductance regulator gene found in a consanguineous Chinese family. Clin. Genet. 47, 124-132 (1995).
39. Moyer BD, Denton J, Karlson KH et al.: A PDZ-interacting domain in CFTR is an apical membrane polarization signal. J. Clin. Invest. 104, 1353-1361 (1999).
40. Mickle JE, Cutting GR: Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clin. Chest Med. 19, 443-458 (1998).
41. Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL: C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J. Biol. Chem. 274, 21873-21877 (1999).
42. Zielenski J: Genotype and phenotype in cystic fibrosis. Respiration 67, 117-183 (2000).
43. Correlation between genotype and phenotype in patients with cystic fibrosis: The Cystic Fibrosis Genotype-Phenotype Consortium. N. Engl. J. Med. 329, 1308-1313 (1993).
44. Kerem E, Corey M, Kerem BS et al.: The relation between genotype and phenotype in cystic fibrosis - analysis of the most common mutation (ΔF508). N. Eng.J. Med. 323, 1517-1522 (1990).
45. Kristidis P, Bozon D, Corey M et al.: Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 50, 178-184 (1992).
46. Hamosh A, Corev M: Correlation between genotype and phenotype in patients with cystic fibrosis. N. Engl. J. Med. 329, 1308-1313 (1993).
47. Di Sant'Agnese PA: Fibrocystic disease of the pancreas, a generalized disease of exocrine glands. JAMA 160(10), 846-853 (1956).
48. Shwachman H, Kulczycki LL, Mueller HL, Flake CG: Nasal polyps in patients with cystic fibrosis. Pediatrics 301, 389-401 (1962).
49. Kaplan R, Shwachman H, Perlmutter AD, Rule A, Khaw KT, Holsclaw DS: Reproductive failure in males with cystic fibrosis. N. Engl. J. Med. 279, 65-69 (1968).
50. Chillon M, Casals T, Mercier B et al.: Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N. Engl. J. Med. 332, 1475-1480 (1995).
51. Anguiano A, Oates RD, Amos JA et al.: Congential bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA 267, 1794-1797 (1992).
52. van der Ven K, Messer L, van der Ven H, Jevendran RS, Ober C: Cystic fibrosis mutation screening in healthy men with reduced sperm quality. Hum. Reprod. II, 513-514. (1996).
53. Augarten A, Kerem BS, Yahav Y et al.: Mild cystic fibrosis and normal or borderline sweat test in patients with 3849p10kb C-T mutation. Lancet 342, 25-26 (1993).
54. Highsmith WE, Burch LH, Zhou Z et al.: A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N. Engl. J. Med. 331, 974-980 (1996).
55. Gazvani R, Lewis-Jones DI: Cystic fibrosis mutation screening before assisted reproduction. Int. J. Androl. 27(1), 1-4 (2004).
56. Groman JD, Meyer ME, Wilmott RW, Zeidin PL, Cutting GR: Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N. Engl. J. Med. 347, 401-407 (2002).
57. Merlo AC, Boyle MP: Modifier genes in cystic fibrosis lung diseas. J. Lab. Clin. Med. 141, 237-241 (2002).
58. Rozmahel R, Wilschanski M, Matin A et al.: Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat. Genet. 12, 280-287 (1996).
59. Zielenski J, Corey M, Rozmahel R et al.: Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat. Genet. 22, 128-129 (1999).
60. Garred P, Pressler T, Madsen HO et al.: Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J. Clin. Invest. 104, 431-437 (1999).
61. Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C: Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. Br. Med. J. 319, 1166-1167 (1999).
62. Arkwright PD, Laurie S, Super M et al.: TGF-β(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 55,459-462 (2000).
63. Bonfield TL, Panuska JR, Konstan MW et al.: Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care. Med. 152, 2111-2118 (1995).
64. Greally P, Hussein MJ, Cook AJ, Sampson AP, Piper PJ, Price JF: Sputum tumor necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch. Dis. Child. 68, 389-392 (1993).
65. Garred P, Pressler T, Lanng S et al.: Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr. Pulmonol. 33, 201-207 (2002).
66. Dotsch J, Puls J, Klimek T, Rascher W: Reduction of neuronal and inducible nitric oxide synthase gene expression in patients with cystic fibrosis. Eur. Arch. Otorhinolaryngol. 259, 222-226 (2002).
67. Texereau J, Marullo S, Hubert D et al.: Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis. Thorax 4(59), 156-158 (2004).
68. Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE: Influence of neonatal screening and centralised treatment on long-term clinical outcome and survival of CF patients. Eur. Respir. J. 18, 306-315 (2001).
69. Farrell PM, Li Z, Korosok MR, Laxova A et al.: Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am. J. Respir. Crit. Care. Med. 168, 1100-1108 (2003).
70. Castellani C: Evidence for newborn screening for cystic fibrosis. Paediatr. Respir. Rev. 4, 278-284 (2003).
71. Farrell MH, Farrell PM: Newborn screening for cystic fibrosis: ensuring more good than harm. J. Pediatr. 143, 707-712 (2003)
72. Wilcken B, Wiley V: Newborn screening methods for cystic fibrosis. Paediatr. Respir. Rev. 4, 272-277 (2003).
73. Gelman MS, Kopito RR: Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. J. Clin. Invest. 110, 1591-1597 (2002).
74. Powell K, Zeitlin PL: Therapeutic approaches to repair defects in ΔF508 CFTR folding and cellular targeting. Adv. Drug Deliv. Rev. 54, 1395-1408 (2002).
75. Kopito RR: Biosynthesis and degradation of CFTR. Physiol. Rev. 79(Suppl.), S167-S173 (1999).
76. Qu BH, Strickland E, Thomas PJ: Cystic fibrosis: a disease of altered protein folding. J. Bioenerg. Biomembr. 29, 483-490 (1997 ).
77. Zhang F, Kartner N, Lukacs GL: Limited proteolysis as a probe for arrested conformational maturation of ΔF508 CFTR. Nat. Struct. Biol. 5, 180-183 (1998).
78. Kalin N, Claass A, Sommer M et al.: ΔF508 CFTR protein expression in tissues from patients with cystic fibrosis. J. Clin. Invest. 103, 1379-1389 (1999).
79. Penque D, Mendes F, Beck S et al.: Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab. Invest. 80, 857-868 (2000).
80. Ellgaard L, Molinari M, Helenius A: Setting the standards: quality control in the secretory pathway. Science 286, 1882-1888 (1999).
81. Hamilton JW: Gentamicin in pharmocogenetic approach to treatment of cystic fibrosis. Lancet 358, 2014-2016 (2001).
82. Wilschanski M, Yahav Y, Yaacov Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349, 1433-1441 (2003).
83. Gorini L, Kataja E: Phenotypic repair by streptomycin of defective genotypes in E. coli. Proc. Natl. Acad. Sci. USA 51, 487-493 (1964).
84. Buchanan JH, Stevens A, Sidhu J: Aminoglycoside antibiotic treatment of human fibroblasts: intracellular accumulation, molecular changes and the loss of ribosomal accuracy. Eur. J. Cell Biol. 43, 141-147 (1987).
85. Howard M, Frizzell RA, Bedwell DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2, 467-469 (1996).
86. Bedwell DM, Kaenjak A, Benos DJ et al.: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. 3, 1280-1284 (1997).
87. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR: Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271, 635-638 (1996).
88. Fischer H, Fukuda N, Barbry P, Illek B, Sartori C, Matthay MA: Partial restoration of defective chloride conductance in ΔF508 CF mice by trimethylamine oxide. Am. J. Physiol. Lung Cell Mol. Physiol. 281, L52-L57 (2001).
89. Morello JP, Petaja-Repo UE, Bichet DG, Bouvier M: Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci. 21, 466-469 (2000).
90. Hartl FU: Molecular chaperones in cellular protein folding. Nature 381, 571-579 (1996).
91. Yang Y, Janich S, Cohn JA, Wilson JM: The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a preGolgi nonlysosomal compartment. Proc. Natl. Acad. Sci. USA 90, 9480-9484 (1993).
92. Pind S, Riordan JR, Williams DB: Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269, 12784-12788 (1994).
93. Kruh J: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem. 42, 65-82 (1982).
94. Andersson C, Roomans GM: Activation of ΔF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur. Respir. J. 15, 937-941 (2000).
95. Rubenstein RC, Zeitlin PL: A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care. Med. 157, 484-490 (1998).
96. McCarty NA, Standaert TA, Teresi M et al.: A Phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr. Pulmonol. 33, 90-98 (2002).
97. - secretion in Calu-3 airway epithelial cells. Am. J. Physiol. 277, L700-L708 (1999).
98. Moyer BD, Loffing-Cueni D, Lofting J, Reynolds D, Stanton BA: Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells. Am. J. Physiol. 277, F271-F276 (1999).
99. Loffing-Cueni D, Loffing J, Shaw C et al.: Trafficking of GFP-tagged ΔF508-CFTR to the plasma membrane in a polarized epithelial cell line. Am. J. Physiol. Cell Physiol. 281, C1889-C1897 (2001).
100. - secretory capacity by butyrate. J. Clin. Invest. 101, 2072-2079 (1998).
101. Choo-Kang LR, Zeitlin PL: Induction of HSP70 promotes ΔF508 CFTR trafficking. Am. J. Physiol. Lung Cell Mol. Physiol. 281, L58-L68 (2001).
102. Rubenstein RC, Zeitlin PL: Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR. Am. J. Physiol. Cell Physiol. 278, C259-C267 (2000).
103. Liu L, Shack S, Stetler-Stevenson WG, Hudgins WR, Samid D: Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Invest. Dermatol. 103, 335-340 (1994).
104. Newmark HL, Young CW: Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell Biochem. 22(Suppl.), 247-253 (1995).
105. Wood CG, Lee C, Greyhack JT, Kozlowski JM: Phenylacetate and phenylbutyrate promote cellular differentiation in human prostate cancer systems (Meeting abstract). Proc. Annu. Meet. Am. Assoc. Cancer Res. 35, A2404 (1994).
106. Garcia-Bermejo L, Vilaboa NE, Perez C, Galan A, De Blas E, Aller P: Modulation of heat-shock protein 70 (HSP70) gene expression by sodium butyrate in U-937 promonocytic cells: relationships with differentiation and apoptosis. Exp. Cell Res. 236, 268-274 (1997).
107. Choo-Kang LR, Zeitlin PL: Induction of HSP70 promotes ΔF508 CFTR trafficking. Am. J. Physiol. Lung Cell Mol. Physiol. 281, L58-L68 (2001).
108. Zaman K, McPherson M, Vaughan J et al.: S nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation. Biochem. Biophys. Res. Commun. 2841, 65-70 (2001).
109. Andersson C, Gaston B, Roomans GM: S-Nitrosoglutathione induces functional ΔF508-CFTR in airway epithelial cells. Biochem. Biophys. Res. Commun. 297, 552-557 (2002).
110. Chappe V, Mettey Y, Vierfond JM et al.: Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br. J. Pharmacol. 123, 683-693 (1998).
111. Srivastava M, Eidelman O, Pollard HB:. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis. Mol. Med. 5, 753-767 (1999).
112. Eidelman, O, Zhang J, Srivastava M, Pollard HB: Cystic fibrosis and the use of pharmacogenomics to determine surrogate end points for drug discovery. Am. J. Pharmacogenomics 1, 221-238 (2001).
113. He Z, Raman S, Gun Y et al.: Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms. Am. J. Physiol. 275, C958-C966 (1998).
114. Arispe N, Ma J, Jacobson KA, Pollard HB: Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl- 1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylzanthine (DAX). J. Biol. Chem. 273, 5727-5734 (1997).
115. Cohen BE, Lee G, Jacobson KA Yet al.: 8-Cyclopentyl- 1,3-dipropylxanthine and other xanthines differentially bind to the wild type and F508del first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry 36, 6455-6461 (1997).
116. Drumm ML, Wilkinson DJ, Smit LS et al.: Chloride conductance expressed by ΔF508 and other mutant CFTRs in Xenopus oocytes. Science 254, 1797-1799 (1991).
117. Haws CM, Nepomuceno IB, Krouse ME et al.: ΔF508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am. J. Physiol. 270, C1544-C1555 (1996).
118. Luo J, Zhu T, Evagelidis A et al.: Role of protein phosphatases in the activation of CFTR (ABCC7) by genistein and bromotetramisole. Am. J. Physiol. Cell. Physiol. 279, C108-C119 (2000).
119. Becq F, Jensen TJ, Chang XB et al.: Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc. Natl. Acad. Sci. USA 91, 9160-9164 (1994).
120. - conductance of human airway epithelium in vitro and in vivo. Am. J. Physiol. 275, L902-L910 (1998).
121. Reenstra WW, Yurko-Mauro K, Dam A, Raman S, Shorten S: CFTR chloride channel activation by genistein: the role of serine/threonine protein phosphatases. Am. J. Physiol. 271, C650-C657 (1996).
122. Chiang CE, Chen SA, Chang MS, Lin CI, Luk HN: Genistein directly induces cardiac CFTR chloride current by tyrosine kinase-independent and protein kinase A-independent pathway in guinea-pig ventricular myocytes. Biochem. Biophys. Res. Commun. 235, 74-78 (1997).
123. Illek B, Fischer H, Machen TE: Alternate stimulation of apical CFTR by genistein in epithelia. Am. J. Physiol. 270, C265-C275 (1996).
124. Randak C, Auerswald EA, Assfalg-Machleidt I, Reenstra WW, Machleidt W: Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein. Biochem. J. 340(Part 1), 227-235 (1999).
125. Andersson C, Roomans GM: Activation of DF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylhutyrate, genistein and CPX. Eur. Respir J. 15, 937-947 (2000).
126. Fischer H, Schwarzer C, Illek B: Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel. Proc. Natl. Acad. Sci. USA 101, 3691-3696 (2004).
127. Knowles MR, Church NL, Waltner WE et al.: A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N. Engl. J. Med. 322, 1189-1194 (1990).
128. Knowles MR, Clarke LL, Boucher RC: Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N. Engl. J. Med. 325, 533-538 (1991).
129. Rodgers HC, Knox AJ: The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur. Respir. J. 14, 693-696 (1999).
130. Noone PG, Hamblett N, Accurso F et al.: Safety of aerosolized INS 365 in patients with mild-to-moderate cystic fibrosis: results of a Phase I multi-center study. Pediatr. Pulmonol. 32, 122-128 (2001).
131. Nadler SG, Tepper MA, Schacter B, Mazzucco CE: Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat-shock proteins. Science 258, 484-486 (1992).
132. Jiang C, Fang SL, Xiao YF et al.: Partial restoration of cAMP-stimulated CFTR chloride channel activity in ΔF508 cells by deoxyspergualin. Am. J. Physiol. 275, C171-C178 (1998).
133. Egan ME, Glockner-Pagel J, Ambrose C et al.: Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. 8, 485-492 (2002).
134. Egan ME, Pearson M, Weiner SA et al.: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304(5670), 600-602 (2004).
135. Pind S, Riordan JR, Williams DB: Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269, 12784-12788 (1994).
136. Tabcharani JA, Chang XB, Riordan JR, Hanrahan JW: The cystic fibrosis transmembrane conductance regulator chloride channel. Iodide block and permeation. Biophys. J. 62, 1-4 (1992).
137. McPherson MA, Pereira MM, Russell D et al.: The CFTR-mediated protein secretion defect: pharmacological correction. Pflugers Arch. 443(Suppl. 1), S121-S126 (2001).
138. Dormer RL, Derand R, McNeilly CM et al.: Correction of delF5O8-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell Sci. 114, 4073-4081 (2001).
139. Marcet B, Becq F, Norez C, Delmas P, Verrier B: General anesthetic octanol and related compounds activate wild type and F508del cystic fibrosis chloride channels. Br. J. Pharmacol. 141 (6), 905-914 (2004).
140. Rossi L, Castro M, D'Orio F et al.: Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol. Dis. 33, 57-63 (2004).
141. Eidelman O, Srivastava M, Zhang J et al.: Control of the pro-inflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-αR/NFκB pathway. Mol. Med. 7, 523-534 (2001).
142. Hoffmann E, Dittrich-Breiholz O, Hohmann H, Kracht M: Multiple control of interleukin-8 gene expression. J. Leukocyte Biol. 72, 847-854 (2002).
143. Srivastava M, Eidelman O, Zhang J et al.: Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosislung epithelial cells. Proc. Natl. Acad. Sci. USA 101, 7693-7698 (2004).
144. Galietta LV, Jayaraman S, Verkman AS: Cell-based assay for highthroughput quantitative screening of CFTR chloride transport agonists. Am. J. Physiol. Cell Physiol. 281, C1734-C1742 (2001).
145. Ma T, Vetrivel L, Yang H et et al.: High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J. Biol. Chem. 277, 37235-37241 (2002).
146. Zhu H, Zhu JX, Lo PS et al.: Rescue of defective pancreatic secretion in cystic-fibrosis cells by suppression of a novel isoform of phospholipase C. Lancet 362(9401), 2059-2065 (2003).
147. Drumm ML, Pope HA, Cliff WH et al.: Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 62, 1227-1233 (1990).
148. Alton EW, Middleton PG, Caplen NJ et al.: Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat. Genet. 5, 1035-1042 (1993).
149. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ: Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75, 207-216 (1993).
150. Harvey B, Hackett NR, Crystal RG: Correlation between pre-existing systemic antiadenovirus neutralizing antibody titers and lung airway epithelial cell gene transfer following adenovirus vector administration to human lung airways. Pediatr. Pulmonol. 24(Suppl.), 212 (2002).
151. Alton EW, Stern M, Farley R et al.: Cationic lipid mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353, 947-954 (1999).
152. Caplen NJ, Alton EW, Middleton PG et al.: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat. Med. 1, 39-46 (1995).
153. Gill DR, Southern KW, Mofford KA et al.: A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4, 199-209 (1997).
154. Hyde SC, Southern KW,, Gileadi U et al.: Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 7, 1156-1165 (2000).
155. Noone PG, Hohneker KW, Zhou Z et al.: Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol. Ther. 1, 105-114 (2000).
156. Porteous DJ, Dorin JR, McLachlan G et al.: Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4, 210-218 (1997).
157. Ruiz FE, Clancy JP, Perricone MA et al.: A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum. Gene Ther. 12, 751-761 (2001).
158. Zabner J, Cheng SH, Meeker D et al.: Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J. Clin. Invest. 100, 1529-1537 (1997).
159. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC: Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat. Genet. 2, 21-25 (1992).
160. Davies JC, Geddes DM, Alton EW: Gene therapy for cystic fibrosis, J. Gene Med. 3, 409-417 (2001).
161. Koehler DR, Hitt MM, Hu J: Challenges and strategies for cystic fibrosis lung gene therapy. Mol. Ther. 4, 84-91 (2001).
162. Klink DT, Glick MC, Scanlin TF: Gene therapy of cystic fibrosis (CF) airways: a review emphasizing targeting with lactose. Glycoconjugate J. 18, 731-740 (2001).
163. Kreda SM, Pickles RJ, Lazarowski ER, Boucher RC: G protein-coupled receptors as targets for gene transfer vectors using natural small-molecule ligands. Nat. Biotechnol. 18, 635-640 (2000).
164. Johnson LG: Retroviral approaches to gene therapy of cystic fibrosis. Ann. NY Acad. Sci. 953, 43-52 (2001).
165. Gruenert DC: Gene correction with small DNA fragments. Curr. Res. Mol. Ther. 1, 607-613 (1998).
166. Lai LW, Lien YH: Homologous recombination based gene therapy. Exp. Nephrol. 7, 11-14 (1999).
167. Goncz KK, Kunzelmann K, Xu Z, Gruenert DC: Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum. Mol. Genet. 7, 1913-1919 (1998).
168. Kunzelmann K, Legendre JY, Knoell DL, Escobar LC, Xu Z, Gruenert DC: Gene targeting of CFTR DNA in CF epithelial cells. Gene Ther. 3, 859-867 (1996).
169. Sangiuolo F, Bruscia E, Serafino A et al.: In vitro correction of cystic fibrosis epithelial cell lines by small fragment homologous replacement (SFHR) technique. BMC Med. Genet. 3, 8-19 (2002).
170. Bruscia E, Sangiuolo F, Sinibaldi P, Goncz KK, Novelli G, Gruenert DC: Isolation of CF cell lines corrected at ΔF508-CFTR locus by SFHR-mediated targeting. Gene Ther. 9, 683-685 (2002).
171. Goncz KK, Colosimo A, Dallapiccola B et al.: Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR. Gene Ther. 8, 961-965 (2001).
172. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA: In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19(12), 1117-1118 (2001).
173. Zwaka TP, Thomson JA: Homologous recombination in human embryonic stem cells. Nat. Biotechnol. 21(3), 319-321 (2003).